Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent - Wikidata - wikimedia - TriplyDB

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent

http://www.wikidata.org/entity/Q41327770

about

Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines Repurposing medicinal compounds for blood cancer treatment.Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.The Biological Activities of Sesterterpenoid-Type Ophiobolins.Bacterial xenophagy and its possible role in cancer: A potential antimicrobial strategy for cancer prevention and treatment.Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels.Clarithromycin as a "repurposing drug" against MALT lymphoma.A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug repurposing research in epilepsy.Roxithromycin monotherapy inducing a partial response in a patient with myeloma: a case report.Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

P2860

Q30367534-3D378475-13B7-462A-A4E8-2EFBC6EE8D31 Q35807959-A017E236-6B99-434A-9E33-B9FE90018D61 Q37679904-9E23F848-B86A-4005-8E4A-B1D97D31D03C Q38656001-457161C1-A7CB-42B5-8F2C-6E8F7FDBE7CE Q40420981-226DB1F5-688C-43B0-8DB3-02769E1EC2B1 Q42577166-C8E98E48-7D82-481F-A65F-C5F6885301FD Q48298220-9EC53B2A-EA1E-4EEC-B5BB-469CED4A5648 Q49900433-68E64EF7-28FE-4190-8C88-BD9E897EC149 Q50010969-AA395031-31FF-4EB6-9714-E7CCCCABF9C4 Q55188922-CDF484A1-AFE7-47B7-8548-920D715371E0 Q55247585-0D866E95-15C1-4A4A-A0A3-E911C4EE992A Q58786182-B3FE4F33-6874-4A00-BF1D-32498EF80562

P2860

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent

http://www.wikidata.org/entity/Q41327770

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent

@en

type

label

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent

@en

prefLabel

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent

@en

P1433

Q41327770-8560985D-D572-46FE-928C-AB27F17C2F5F

P1476

Q41327770-BEF49D45-D126-48BB-8F4C-89097DBB2092

P2093

Q41327770-2D8D3912-F03D-493C-BF25-050BDB982214

Q41327770-6C97FC6F-EF55-4EAE-92B1-5F16D4E968F6

Q41327770-D489C759-15B4-47F1-A88B-147DB26E5A79

Q41327770-F9164B3C-4EF1-4597-925B-9085AE5B5101

P2860

Q41327770-05CA19BD-E57E-4B27-A58F-5B3CC50C98C2

Q41327770-0F458D4F-6800-4CB1-9DA4-C62DF3A77C49

Q41327770-1C93E221-A6AC-423F-941A-6343EA113D25

Q41327770-1FA0D490-4916-4620-83C4-D7ECFF33E602

Q41327770-21A33BD1-4D23-4106-B64E-63D61515C388

Q41327770-22156B85-F1E9-4565-937E-252F4017E58D

Q41327770-2359ED56-8848-497C-A148-1715D351C0B3

Q41327770-25E2186F-59FB-46BF-84FD-9B011CB46DF5

Q41327770-26106A10-D634-4C5E-AEDD-5AE793A96787

Q41327770-28754C45-1564-4EAF-BAF9-C1C8C043F111

P304

Q41327770-FEFB2F22-56FD-45A7-8A07-2D3C737F1FEB

P31

Q41327770-92B5B346-6DD7-404B-968D-E60404820806

P356

Q41327770-D7FA6E6E-95DC-4196-9BC7-122B46E7FC89

P478

Q41327770-98542050-FDA0-4883-B037-99E999ACD2D4

P50

Q41327770-5A357F96-BC57-4EBF-8DE3-1FC14886DF6D

Q41327770-9FEA381B-4827-4A03-A65C-00559E283709

P577

Q41327770-CEC96DBD-21F3-49C4-AB46-6BDEF79641E6

P5875

Q41327770-E87EDA82-EDBB-46E8-B0F7-B04023E7F732

P698

Q41327770-177DEC26-9B25-4FA4-99F0-8E724B922E28

P932

Q41327770-9D6691D2-F699-4A1E-B2AF-10AE48829848

P356

ECANCER.2015.513

P1433

Ecancermedicalscience

P1476

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent

@en

P2093

Gauthier Bouche

http://www.w3.org/2001/XMLSchema#string

Lydie Meheus

http://www.w3.org/2001/XMLSchema#string

Vidula Sukhatme

http://www.w3.org/2001/XMLSchema#string

Vikas P Sukhatme

http://www.w3.org/2001/XMLSchema#string

P2860

Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Autophagy in the immune system

Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis

Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment

Therapeutic effect of clarithromycin on a transplanted tumor in rats

Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia.

P304

513

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3332/ECANCER.2015.513

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

An M T Van Nuffel

P577

2015-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273065525

http://www.w3.org/2001/XMLSchema#string

P698

25729426

http://www.w3.org/2001/XMLSchema#string

P932

4341996

http://www.w3.org/2001/XMLSchema#string